Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Get Alerts APLS Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following September investor conferences:
- Wells Fargo Annual Healthcare Conference 2024: Fireside chat on Thursday, September 5, 2024, at 9:30 a.m. ET
- Baird 2024 Global Healthcare Conference: Fireside chat on Wednesday, September 11, 2024, at 9:05 a.m. ET
The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
[email protected]
617.599.8178
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- $120,000 and One Million Visitors in 48 Hours for Solo Founder's Side Project Outbid.lol
- Best Crypto to Buy Now Is Not ETH or SOL and Pepeto Proves Why Before
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share